Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06588595 · ClinicalTrials.gov registry record · Phase 4
The Switching Antiplatelet-9 (SWAP-9) Study
A Phase 4 study of Coronary Arterial Disease (CAD), sponsored by University of Florida.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT06588595 is a Phase 4 study of Coronary Arterial Disease (CAD) that is actively recruiting participants, run by University of Florida. The registered enrollment target is 90 participants, below the 3,061-participant average among 5 other Coronary Arterial Disease (CAD) trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06588595, a Phase 4 study of Coronary Arterial Disease (CAD), is actively recruiting participants, sponsored by University of Florida.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the pharmacodynamic effects of ABCD-GENE guided vs. unguided de-escalation strategies among patients on dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI).
Conditions Studied
Interventions
- DRUG Prasugrel/Ticagrelor monotherapy or aspirin plus clopidogrel
- DRUG Aspirin plus clopidogrel
Study Locations (1)
Florida
- University of Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2024-11-01 |
| Est. Completion | 2027-02-28 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06588595
The ClinicalTrials.gov registry entry for NCT06588595 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,061-participant average among 5 other Coronary Arterial Disease (CAD) trials with a reported enrollment target (97% lower). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Coronary Arterial Disease (CAD) appearing as the primary indexed condition, and to 2 interventions - of which Prasugrel/Ticagrelor monotherapy or aspirin plus clopidogrel is the first listed.
NCT06588595 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06588595 about?
NCT06588595 is a clinical study titled "The Switching Antiplatelet-9 (SWAP-9) Study". The purpose of this study is to compare the pharmacodynamic effects of ABCD-GENE guided vs. unguided de-escalation strategies among patients on dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI).
What is the current status of trial NCT06588595?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 90 participants. The study started on 2024-11-01. Estimated completion is 2027-02-28.
What conditions does trial NCT06588595 study?
This clinical trial studies the following conditions: Coronary Arterial Disease (CAD).
What interventions are being tested in trial NCT06588595?
The interventions under investigation include: Prasugrel/Ticagrelor monotherapy or aspirin plus clopidogrel (DRUG), Aspirin plus clopidogrel (DRUG).
Who is sponsoring clinical trial NCT06588595?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06588595 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Arterial Disease (CAD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)
RECRUITING · Phase 4
-
Focused Orticumab Research for Treating Inflammation in Coronary Arteries
RECRUITING · Phase 2
-
FORWARD CAD IDE Study
RECRUITING · NA
-
AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions
RECRUITING · NA
-
Genetic Testing of CYP2C19 in Prognostic Evaluation of Long-Term Major Adverse Cardiac and Vascular Events
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.